Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Glioblastoma × Naltrexone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Substance Withdrawal Syndrome 1 Prostatic Neoplasms 1 Overweight 1 Obesity 1 Melanoma 1 Kidney Neoplasms 1 Glioma 1 Glioblastoma 1 Chronic Pain 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Temozolomide 104 Bevacizumab 64 Radiotherapy 45 Radiation 21 Erlotinib Hydrochloride 12 pembrolizumab 10 Magnetic Resonance Spectroscopy 10 Lomustine 10 Vorinostat 9 Irinotecan 9 Nivolumab 8 Surgical Procedures, Operative 7 Radiotherapy, Intensity-Modulated 7 Immunoglobulin G 7 Disulfides 7 Sorafenib 6 Radiotherapy, Conformal 6 Radiosurgery 6 Drug Therapy 6 Carmustine 6 antineoplaston AS 2-1 5 antineoplaston A10 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 Everolimus 5 veledimex 4 selinexor 4 sargramostim 4 cediranib 4 Dasatinib 4 Cilengitide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡